P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia by B. Hajarizadeh, J. Grebely, G.V. Matthews, M. Martinello, G.J. Dore

Connect to this object online.

O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study by M. Alavi, J. Amin, J. Grebely, M.G. Law, N.Z. Janjua, M. Krajden, B. Hajarizadeh, J. George, G.V. Matthews, S. Larney, L. Degenhardt, G.J. Dore

Connect to this object online.

P6 Phylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015 by S.R. Bartlett, T. Applegate, B. Jacka, F. Lamoury, R. Bull, M. Danta, D. Bradshaw, A.R. Lloyd, M. Hellard, G.J. Dore, G.V. Matthews, J. Grebely

Connect to this object online.

O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective by J.S. Doyle, A.L. Bowring, J. Cutts, J. Roney, D.M. Iser, J. Sasadeusz, M. O'Reilly, C. Fairley, E. Gane, J. Hoy, G.V. Matthews, N. Medland, R. Moore, M. Prins, M. Stoové, B.K. Tee, M.E. Hellard

Connect to this object online.

O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study by J. Grebely, O. Dalgard, B. Conway, E. Cunningham, P. Bruggmann, B. Hajarizadeh, J. Amin, P. Marks, S. Quiene, T.L. Applegate, T. Swan, J. Byrne, M. Lacalamita, A. Dunlop, J. Bruneau, M.E. Hellard, G.V. Matthews, J. Powis, D. Shaw, M.C. Thurnheer, M. Weltman, I. Kronborg, C. Cooper, J.J. Feld, C. Fraser, A. Litwin, J. Dillon, P. Read, E. Gane, G.J. Dore

Connect to this object online.